[Federal Register Volume 76, Number 243 (Monday, December 19, 2011)]
[Notices]
[Pages 78671-78672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-32424]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Drugged Driving: Future Research Directions (5569).
    Date: January 11, 2012.
    Time: 12 p.m. to 5 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D. Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, (301) 402-6626, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Feasibility of Development of RNAi-based 
Therapeutics for Treatment of HIV and HVC Infections in Drug Abusing 
Populations (8907).
    Date: January 13, 2012.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Minna Liang, Ph.D., Scientific Review Officer, 
Grants Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4226, 
MSC 9550, Bethesda, MD 20892-9550, (301) 435-1432, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of a Solid Dosage Form for Fenobam 
(8906).
    Date: January 18, 2012.
    Time: 11 a.m. to 5 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive

[[Page 78672]]

Boulevard Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, 6001 Executive Blvd. Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, (301) 402-6626, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Smokescreen: Genetic Screening Tool for Tobacco 
Dependence and Treatment Approaches (7783).
    Date: January 19, 2012.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Minna Liang, Ph.D., Scientific Review Officer, 
Grants Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse, NIH, 6001 Executive Blvd. Room 4226, MSC 
9550, Bethesda, MD 20892-9550, (301) 435-1432, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: December 13, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-32424 Filed 12-16-11; 8:45 am]
BILLING CODE 4140-01-P